BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial.

ABSTRACT:

Background and purpose

Dose-escalation in rectal cancer (RCa) may result in an increased complete response rate and thereby enable omission of surgery and organ preservation. In order to implement dose-escalation, it is crucial to develop a technique that allows for accurate image-guided radiotherapy. The aim of the current study was to determine the performance of a novel liquid fiducial marker (BioXmark®) in RCa patients during the radiotherapy course by assessing its positional stability on daily cone-beam CT (CBCT), technical feasibility, visibility on different imaging modalities and safety.

Materials and methods

Prospective, non-randomized, single-arm feasibility trial with inclusion of twenty patients referred for neoadjuvant chemoradiotherapy for locally advanced RCa

SUBMITTER: Opbroek TJS 

PROVIDER: S-EPMC9668658 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature